Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021
February 24 2021 - 7:00AM
Business Wire
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome
platform company developing a novel class of multifunctional
bacterial therapeutics designed to functionally interact with host
cells and tissues to treat disease, today announced that management
will host a conference call and live audio webcast on March 2, 2021
at 8:30 a.m. ET to discuss fourth quarter and full year 2020
results and provide a general business update.
To access the conference call, please dial 844-277-9450
(domestic) or 336-525-7139 (international) and reference the
conference ID number 1038426. To join the live webcast, please
visit the “Investors and Media” section of the Seres website at
www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease.
Seres’ SER-109 program achieved the first-ever positive pivotal
clinical results for a targeted microbiome drug candidate and has
obtained Breakthrough Therapy and Orphan Drug designations from the
FDA. The SER-109 program is being advanced for the treatment of
recurrent C. difficile infection and has potential to become a
first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287
program has obtained Fast Track and Orphan Drug designations from
the FDA and is being evaluated in a Phase 2b study in patients with
active mild-to-moderate ulcerative colitis. Seres is evaluating
SER-401 in a Phase 1b study in patients with metastatic melanoma,
SER-301 in a Phase 1b study in patients with ulcerative colitis,
and SER-155 to prevent mortality due to gastrointestinal
infections, bacteremia and graft versus host disease. For more
information, please visit www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005201/en/
PR Kristin Ainsworth kainsworth@serestherapeutics.com
IR Carlo Tanzi, Ph.D. ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024